Cargando…

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tohyama, Osamu, Matsui, Junji, Kodama, Kotaro, Hata-Sugi, Naoko, Kimura, Takayuki, Okamoto, Kiyoshi, Minoshima, Yukinori, Iwata, Masao, Funahashi, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177084/ https://www.ncbi.nlm.nih.gov/pubmed/25295214 http://dx.doi.org/10.1155/2014/638747

Ejemplares similares

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
por: Enomoto, Keisuke, et al.
Publicado: (2021)

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
por: Matsuki, Masahiro, et al.
Publicado: (2017)

E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
por: Wiegering, Armin, et al.
Publicado: (2014)

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants
por: Shumaker, Robert, et al.
Publicado: (2015)

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
por: Matsuki, Masahiro, et al.
Publicado: (2018)

Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model
por: Nakazawa, Youya, et al.
Publicado: (2015)

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
por: Kimura, Takayuki, et al.
Publicado: (2018)

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
por: Hong, David S., et al.
Publicado: (2015)

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
por: Cabanillas, Maria E., et al.
Publicado: (2015)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013)

Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
por: Ichikawa, Kenji, et al.
Publicado: (2020)

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
por: Glen, Hilary, et al.
Publicado: (2011)

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
por: Adachi, Yusuke, et al.
Publicado: (2022)

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
por: Boss, D S, et al.
Publicado: (2012)

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
por: Yamamoto, Yuji, et al.
Publicado: (2014)

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2020)

LINC02688 and PP7080 as novel biomarkers in early diagnosis of gastric cancer
por: Fattahi, Sadegh, et al.
Publicado: (2021)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
por: Keizer, Ron J., et al.
Publicado: (2010)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer
por: Su, Xi, et al.
Publicado: (2020)

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
por: Nakagawa, Takayuki, et al.
Publicado: (2014)

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study
por: Finn, Richard S., et al.
Publicado: (2021)

M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
por: Yang, Long, et al.
Publicado: (2023)

Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib
por: Saito, Kei, et al.
Publicado: (2020)

Synergistic Effect of Lenvatinib and Chemotherapy in Hepatocellular Carcinoma Using Preclinical Models
por: Wang, Mingxun, et al.
Publicado: (2023)

Mutations in pmrB Confer Cross-Resistance between the LptD Inhibitor POL7080 and Colistin in Pseudomonas aeruginosa
por: Romano, Keith P., et al.
Publicado: (2019)

Long noncoding RNA PP7080 promotes hepatocellular carcinoma development by sponging mir-601 and targeting SIRT1
por: Song, Weifang, et al.
Publicado: (2021)

Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model
por: Suzuki, Kensuke, et al.
Publicado: (2022)

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
por: Takeda, Haruhiko, et al.
Publicado: (2019)

Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway
por: Hao, Jianwen, et al.
Publicado: (2021)

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro
por: Wang, Xinyue, et al.
Publicado: (2023)

Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
por: Ito, Ken, et al.
Publicado: (2015)

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2016)

Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2017)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
por: Kawamura, Yoshifumi, et al.
Publicado: (2021)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
por: Lorusso, Loredana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9aslhdj4hp4q59fl57lhr66b8e